☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
stage IV
AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage I...
May 7, 2021
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV Bladder Cancer
March 6, 2020
AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancer
August 21, 2019
Load more...
Back to Home
